Revenue in 2024 is expected to grow approximately 56% compared to 2023, approximately $53 million above the upper financial forecast
Additional business updates to be presented by Natera (NASDAQ: ) at JP Morgan’s 43rd Annual Healthcare Conference on January 15, 2025.
AUSTIN, Texas–( BUSINESS WIRE )–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. The company expects the following:
- In total (EPA:) revenues of approximately $472 million in the fourth quarter of 2024 compared to $311 million in the fourth quarter of 2023, an increase of approximately 52%.
- Total revenues of approximately $1.7 billion in full year 2024 compared to $1.1 billion in full year 2023, an increase of approximately 56%.
- Approximately 792,800 tests were processed in Q4 2024 compared to 626,800 tests in Q4 2023, an increase of 26.5%. This included a record quarter for the company’s three flagship products: Panorama™, Prospera™ and Signatera™.
- Approximately 3,064,600 tests were processed in all of 2024 compared to 2,496,100 tests in all of 2023, an increase of 22.8%.
- Approximately 150,800 oncology tests, including approximately 144,500 clinical oncology tests, were processed in the fourth quarter of 2024 compared to 97,500 oncology tests, including 90,500 clinical oncology tests, in the fourth quarter of 2023, an increase of 54.7%. Consequently, clinical oncology tests increased by approximately 14,800 tests in the fourth quarter of 2024 compared to the third quarter of 2024.
- Approximately 528,200 oncology tests, including approximately 498,300 clinical oncology tests, were processed in all of 2024 compared to 341,000 oncology tests, including 305,400 clinical oncology tests, in all of 2023, an increase of 54.9%.
- The company generated positive cash inflows of approximately $45.8 million in the fourth quarter of 2024 compared to cash outflows of $60.8 million in the fourth quarter of 20231.2.
- The company generated positive cash inflows of approximately $86.3 million in the full year 2024 compared to cash outflows of $267.1 million in 20231,2.
These results will be included in a presentation at the JP Morgan Healthcare 43rd Annual Conference on Wednesday, January 15, 2025 at 9:00 a.m. PT and will also be posted on the Investor Relations section of Natera’s website at www .the investor.makes. com. Natera will also present additional business updates at the JP Morgan conference.
Natera plans to announce its full financial results for the fourth quarter and full year 2024 during its February 2025 earnings call.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health and organ health. Our goal is to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests have been validated in more than 250 peer-reviewed publications showing high accuracy. Natera operates ISO 13485-certified and CAP-accredited Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.
Forward-looking statements
This news release contains forward-looking statements, including our preliminary operating and financial results for the fourth quarter and fiscal year ended December 31, 2024. Preliminary Operating and Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2024. they are not audited. by our independent registered public accounting firm and are based on management’s initial review of our business and results for the fiscal year ended. These preliminary operating and financial results are subject to audit based on our year-end closing procedures, final adjustments and an audit by our independent registered public accounting firm. As a result, our actual operating and financial results may differ materially from these preliminary results. In addition, these preliminary operating and financial results are not a comprehensive statement of our operating and financial results for the fourth quarter and fiscal 2024 and should not be viewed as a substitute for complete, audited financial statements prepared in accordance with generally accepted accounting principles. All forward-looking statements contained in this press release are based on Natera’s current plans, estimates and expectations as of the date of this press release and do not constitute a representation that such plans, estimates or expectations will be realized. Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update any forward-looking statements in the future.
Our forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially, including: our preliminary fourth quarter and fiscal 2024 operating and financial results are subject to significant changes and adjustments as noted above; we face numerous uncertainties and challenges in achieving our financial projections and goals; we have incurred net losses since our inception and anticipate that we will continue to incur net losses for the foreseeable future; our quarterly results may vary from period to period; our assessments of market opportunities and predictions of market growth may prove to be incorrect. Additional risks and uncertainties that could affect our financial results are discussed in more detail in the sections entitled “Risk Factors” and Management’s Discussion and Analysis of Financial Condition and Results of Operations in our most recent filings on Forms 10-K and 10-Q and in other filings that we file with the SEC from time to time. These documents are available at www.investor.natera.com and on the SEC’s website at www.sec.gov.
1 Non-GAAP cash flow for the quarter and year ended December 31, 2024 is estimated based on estimated unaudited GAAP cash flow statement amounts, including net cash provided by operating activities, net cash provided by financing activities, and net cash from investment activities excluding amounts related to short-term investments.
2 Non-GAAP cash outflow of $60.8 million for the quarter ended December 31, 2023 is derived from the GAAP Statement of Cash Flows, including $58.1 million of net cash provided by operating activities, $9.5 million USD net cash from investing activities excluding amounts related to offsetting short-term investments for $6.8 million of net cash from financing activities.
Non-GAAP cash outflow of $267.1 million for the year ended December 31, 2023 was derived from the GAAP Statement of Cash Flows, including $246.9 million of net cash provided by operating activities, 39, $2 million of net cash provided by investing activities excluding amounts related to short-term investments, offset by $19.0 million of net cash provided by financing activities excluding Cash inflow of $235.4 million from the public offering in September 2023.
Management uses non-GAAP cash flow as an indicator of the Company’s operating ability to generate cash.
See the original version on businesswire.com: https://www.businesswire.com/news/home/20250112651894/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090, investor@natera.com
Media: Lesley Bogdanow, Vice President of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
